CHICAGO — The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes for patients with early-stage resectable non-small cell lung cancer, according to findings presented at ASCO Annual Meeting.Results of the randomized phase 3 KEYNOTE-671 trial — published simultaneously in The New England Journal of Medicine — showed a
Dr John Friend, chief medical officer (CMO) of Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) will immediately assume the role of chief executive officer.
KAZIA ANNOUNCES EXECUTIVE LEADERSHIP CHANGES Dr John Friend appointed Chief Executive Officer, succeeding Dr James Garner Sydney, 1st May. | May 1, 2023
Helsinn publishes new data evaluating chlormethine gel's mode of action in Dermatology and Therapy Lugano, Switzerland, October 18, 2022 - Helsinn Group ("Helsinn"), a fully integrated, global